(Q37883608)

24 August 2017

1 reference

title

Metformin as an antitumor agent in cancer prevention and treatment (English)

1 reference

24 August 2017

1 reference

Donghui Li

1

1 reference

24 August 2017

1 December 2011

1 reference

24 August 2017

1 reference

24 August 2017

3

1 reference

24 August 2017

4

1 reference

24 August 2017

320-327

1 reference

Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms

24 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2011.00119.X

Chemoprevention meets glucose control

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2011.00119.X

Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2011.00119.X

Sulphonylureas and cancer: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2011.00119.X

New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2011.00119.X

The influence of glucose-lowering therapies on cancer risk in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2011.00119.X

Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2011.00119.X

Long-term metformin use is associated with decreased risk of breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2011.00119.X

Antidiabetic therapies affect risk of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2011.00119.X

Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2011.00119.X

Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2011.00119.X

Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2011.00119.X

Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2011.00119.X

Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2011.00119.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2011.00119.X

Prevention of pancreatic cancer induction in hamsters by metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2011.00119.X

Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2011.00119.X

Protective effect of metformin in CD1 mice placed on a high carbohydrate-high fat diet

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2011.00119.X

Dietary energy availability affects primary and metastatic breast cancer and metformin efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2011.00119.X

Metformin prevents tobacco carcinogen--induced lung tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2011.00119.X

Inflammation and cancer: back to Virchow?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2011.00119.X

21 January 2018

Inflammation and cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2011.00119.X

Metformin: new understandings, new uses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2011.00119.X

The effect of metformin treatment on VEGF and PAI-1 levels in obese type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2011.00119.X

Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2011.00119.X

Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2011.00119.X

Improved endothelial function with metformin in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2011.00119.X

Very high risk of cancer in familial Peutz-Jeghers syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2011.00119.X

AMPK phosphorylation of raptor mediates a metabolic checkpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2011.00119.X

LKB1 and AMPK in cell polarity and division

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2011.00119.X

p53: new roles in metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2011.00119.X

Metformin suppresses intestinal polyp growth in ApcMin/+ mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2011.00119.X

Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2011.00119.X

The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2011.00119.X

Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2011.00119.X

Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2011.00119.X

Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2011.00119.X

Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2011.00119.X

Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2011.00119.X

Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2011.00119.X

Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2011.00119.X

Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2011.00119.X

Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2011.00119.X

Metformin induces unique biological and molecular responses in triple negative breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2011.00119.X

Enhancing CD8 T-cell memory by modulating fatty acid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2011.00119.X

Immunology: A metabolic switch to memory.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2011.00119.X

The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2011.00119.X

Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2011.00119.X

Metformin and other biguanides in oncology: advancing the research agenda

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2011.00119.X

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2011.00119.X

Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2011.00119.X

Is it time to test metformin in breast cancer clinical trials?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2011.00119.X

Metformin in breast cancer: time for action

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2011.00119.X

Incorporating the antidiabetic drug metformin in HER2-positive breast cancer treated with neo-adjuvant chemotherapy and trastuzumab: an ongoing clinical-translational research experience at the Catalan Institute of Oncology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2011.00119.X

Metformin in Cancer Therapy: A New Perspective for an Old Antidiabetic Drug?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2011.00119.X

Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2011.00119.X

Metformin blocks migration and invasion of tumour cells by inhibition of matrix metalloproteinase-9 activation through a calcium and protein kinase Calpha-dependent pathway: phorbol-12-myristate-13-acetate-induced/extracellular signal-regulated [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2011.00119.X

Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2011.00119.X

Ionizing radiation activates AMP-activated kinase (AMPK): a target for radiosensitization of human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2011.00119.X

10.1111/J.1753-0407.2011.00119.X

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference

PubMed ID

21631893